{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:33:47Z","timestamp":1794537227800,"version":"4.9.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.parkreldis.2025.107950","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:17:00Z","timestamp":1752603420000},"page":"107950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cognitive outcomes of infusion therapies in Parkinson's disease: A comprehensive systematic review"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-5498","authenticated-orcid":false,"given":"Michela","family":"Garon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Scharfenort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Ljung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2025.107950_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson pandemic\u2014a call to action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2025.107950_bib2","first-page":"S65","article-title":"The choice between advanced therapies for Parkinson's disease patients: why, what, and when?","volume":"10","author":"Dijk","year":"2020","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107950_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13847","article-title":"The G. study Co-Investigators, Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel","volume":"26","author":"Ray Chaudhuri","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107950_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2092","article-title":"Cognitive function in different motor subtypes of Parkinson's disease: a systematic review protocol","volume":"7","author":"Child","year":"2024","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.parkreldis.2025.107950_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14737175.2018.1535902","article-title":"Rationale and patient selection for interventional therapies in Parkinson's disease","volume":"18","author":"Siddiqui","year":"2018","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.parkreldis.2025.107950_bib6","first-page":"641","article-title":"Infusion therapies in the treatment of Parkinson's disease","volume":"13","author":"van Laar","year":"2023","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107950_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1757","article-title":"LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: review of literature","volume":"10","author":"Kamel","year":"2020","journal-title":"Brain Behav"},{"key":"10.1016\/j.parkreldis.2025.107950_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11910-020-01062-2","article-title":"Infusion therapies for Parkinson's disease","volume":"20","author":"Prakash","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.parkreldis.2025.107950_bib9","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.22596","article-title":"Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life","volume":"24","author":"Honig","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107950_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","article-title":"Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes","volume":"21","author":"Antonini","year":"2015","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","article-title":"Levodopa-carbidopa intestinal gel in advanced Parkinson's: final results of the GLORIA registry","volume":"45","author":"Antonini","year":"2017","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease \u2013 clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jns.2016.11.080","article-title":"Apomorphine pump in advanced Parkinson's disease: effects on motor and nonmotor symptoms with brain metabolism correlations","volume":"372","author":"Auffret","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.parkreldis.2011.08.010","article-title":"Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications","volume":"18","author":"Drapier","year":"2012","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","article-title":"Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment","volume":"3","author":"Ellis","year":"1997","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib16","first-page":"1937","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson's disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study, neurol","volume":"12","author":"Aldred","year":"2023","journal-title":"Ther."},{"key":"10.1016\/j.parkreldis.2025.107950_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70077","article-title":"Cognitive outcomes of advanced therapies in Parkinson's disease: a systematic review of apomorphine and levodopa\u2013carbidopa intestinal gel therapies","volume":"32","author":"Longo","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107950_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neurol.2024.06.008","article-title":"Influence of continuous subcutaneous apomorphine infusion on cognition and behavior in Parkinson's disease: a systematic review","volume":"181","author":"Houvenaghel","year":"2025","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.parkreldis.2025.107950_bib19","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"key":"10.1016\/j.parkreldis.2025.107950_bib20","first-page":"420","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen","year":"2018","journal-title":"J. Med. Libr. Assoc. JMLA"},{"key":"10.1016\/j.parkreldis.2025.107950_bib21","author":"Wells"},{"key":"10.1016\/j.parkreldis.2025.107950_bib22","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. 0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1016\/j.parkreldis.2025.107950_bib23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-126-5-199703010-00006","article-title":"Systematic reviews: synthesis of best evidence for clinical decisions","volume":"126","author":"Cook","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.parkreldis.2025.107950_bib24","article-title":"Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: a prospective study of 22 patients","volume":"6","author":"Fern\u00e1ndez-Pajar\u00edn","year":"2022","journal-title":"Clin Park Relat Disord"},{"key":"10.1016\/j.parkreldis.2025.107950_bib25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/mds.20237","article-title":"Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease","volume":"19","author":"Alegret","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107950_bib26","article-title":"Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study","volume":"7","author":"Meira","year":"2021","journal-title":"Npj Park. Dis"},{"key":"10.1016\/j.parkreldis.2025.107950_bib27","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10072-019-03920-5","article-title":"Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies","volume":"40","author":"Olivola","year":"2019","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.parkreldis.2017.09.025","article-title":"Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: a retrospective long-term follow-up study","volume":"45","author":"Borgemeester","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.107950_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.parkreldis.2009.05.006","article-title":"Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations","volume":"16","author":"van Laar","year":"2010","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.archger.2004.04.039","article-title":"Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years","author":"Morgante","year":"2004","journal-title":"Arch. Gerontol. Geriatr. Suppl."},{"key":"10.1016\/j.parkreldis.2025.107950_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41531-023-00525-w","article-title":"A single centre prospective study of three device-assisted therapies for Parkinson's disease","volume":"9","author":"Morales-Brice\u00f1o","year":"2023","journal-title":"NPJ Park. Dis"},{"key":"10.1016\/j.parkreldis.2025.107950_bib32","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/mdc3.13338","article-title":"Continuous subcutaneous apomorphine infusion before subthalamic deep brain stimulation: a prospective, comparative study in 20 patients","volume":"8","author":"Fern\u00e1ndez-Pajar\u00edn","year":"2021","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107950_bib33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00415-017-8721-7","article-title":"Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson's disease","volume":"265","author":"Duprez","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107950_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jns.2018.10.010","article-title":"Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life","volume":"395","author":"Houvenaghel","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/WNF.0b013e3181a6a92b","article-title":"The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study","volume":"32","author":"Geerligs","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2025.107950_bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jnnp.2005.078659","article-title":"Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus","volume":"77","author":"De Gaspari","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2025.107950_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000067968","article-title":"Dopaminergic modulation of visual-spatial working memory in Parkinson's disease","volume":"15","author":"Costa","year":"2003","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"10.1016\/j.parkreldis.2025.107950_bib38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10072-003-0116-0","article-title":"Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease","volume":"24","author":"Di Rosa","year":"2003","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib39","first-page":"786","article-title":"Dopaminergic modulation of cognition in Parkinson's disease: the effects of apomorphine","volume":"4","author":"Ruzicka","year":"1998","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.parkreldis.2025.107950_bib40","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/jnnp.57.8.998","article-title":"Apomorphine induced cognitive changes in Parkinson's disease","volume":"57","author":"R\u016fzicka","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2025.107950_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0017433","article-title":"Subthalamic nucleus stimulation affects fear and sadness recognition in Parkinson's disease","volume":"24","author":"P\u00e9ron","year":"2010","journal-title":"Neuropsychology"},{"key":"10.1016\/j.parkreldis.2025.107950_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.758","article-title":"Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion","volume":"7","author":"De Fabregues","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.parkreldis.2025.107950_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.848","article-title":"l-Dopa\/carbidopa intestinal gel and subthalamic nucleus stimulation: effects on cognition and behavior","volume":"7","author":"Valldeoriola","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.parkreldis.2025.107950_bib44","article-title":"Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations","author":"Balestrino","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2017.02.001","article-title":"Levodopa\/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: an open-label study","volume":"37","author":"Juh\u00e1sz","year":"2017","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.parkreldis.2016.05.015","article-title":"Advanced therapies in Parkinson's disease: long-term retrospective study","volume":"29","author":"Merola","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2025.107950_bib47","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00702-013-1153-3","article-title":"Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients","volume":"121","author":"Sensi","year":"2014","journal-title":"J Neural Transm Vienna"},{"key":"10.1016\/j.parkreldis.2025.107950_bib48","first-page":"79","article-title":"Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life","volume":"16","author":"Fasano","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib49","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1007\/s00415-020-10018-y","article-title":"Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa","volume":"267","author":"Kulisevsky","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107950_bib50","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mdc3.12526","article-title":"Effect of levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson's disease","volume":"4","author":"Standaert","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107950_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-012-6597-0","article-title":"Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study","volume":"260","author":"Zibetti","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107950_bib52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mds.23524","article-title":"Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease","volume":"26","author":"Merola","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107950_bib53","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2009.10.021","article-title":"Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients","volume":"34","author":"S\u00e1nchez-Casta\u00f1eda","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2025.107950_bib54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.parkreldis.2006.08.006","article-title":"L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease","volume":"13","author":"Ghilardi","year":"2007","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib55","first-page":"379","article-title":"Levodopa-carbidopa intestinal gel for Parkinson's disease over 11 years: one center's \u201creal-world\u201d experience, can","volume":"51","author":"Vekhande","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/jpm12050813","article-title":"On behalf of iCARE-PD Consortium, personalized care in late-stage Parkinson's disease: challenges and opportunities","volume":"12","author":"Fabbri","year":"2022","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.parkreldis.2025.107950_bib57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.parkreldis.2020.10.042","article-title":"Parkinson's disease advanced therapies - a systematic review: more unanswered questions than guidance","volume":"83","author":"Marsili","year":"2021","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib58","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/jpm11080773","article-title":"Personalised advanced therapies in Parkinson's disease: the role of non-motor symptoms profile","volume":"11","author":"Leta","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.parkreldis.2025.107950_bib59","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40266-018-0599-2","article-title":"Adjunctive therapies in Parkinson's disease: how to choose the best treatment strategy approach","volume":"35","author":"Fabbri","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.parkreldis.2025.107950_bib60","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/mds.27002","article-title":"MDS study group \u201cvalidation of mild cognitive impairment in Parkinson disease,\u201d mild cognitive impairment as a risk factor for Parkinson's disease dementia","volume":"32","author":"Hoogland","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2025.107950_bib61","first-page":"183","article-title":"Progression of cognitive decline in Parkinson's disease","volume":"8","author":"Roheger","year":"2018","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107950_bib62","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1073\/pnas.98.1.295","article-title":"Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits","volume":"98","author":"Gao","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/026988119701100208","article-title":"Catecholamine regulation of the prefrontal cortex","volume":"11","author":"Arnsten","year":"1997","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.parkreldis.2025.107950_bib64","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","article-title":"Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations","volume":"33","author":"Carbone","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2025.107950_bib65","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/mdc3.13810","article-title":"Continuous subcutaneous infusion delivery of apomorphine in Parkinson's disease: a systematic review","volume":"10","author":"Kukkle","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.107950_bib66","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and \u03b11\/\u03b12-Adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.parkreldis.2025.107950_bib67","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","article-title":"Kings Parcog groupMDS Nonmotor study group, Amyloid-\u03b2 and Parkinson's disease","volume":"266","author":"Lim","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107950_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2005.03.024","article-title":"Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease","volume":"30","author":"Cools","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.parkreldis.2025.107950_bib69","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.parkreldis.2021.09.022","article-title":"Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: a prospective analysis of the Thai Apomorphine Registry","volume":"91","author":"Phokaewvarangkul","year":"2021","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2025.107950_bib70","first-page":"935","article-title":"Predictors of time to discontinuation of levodopa-carbidopa intestinal gel infusion: a retrospective cohort study","volume":"10","author":"Moes","year":"2020","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2025.107950_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2022.867055","article-title":"Cognitive impact of deep brain stimulation in Parkinson's disease patients: a systematic review","volume":"16","author":"Ra\u010dki","year":"2022","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.parkreldis.2025.107950_bib72","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s10072-024-07953-3","article-title":"A predictive model for longitudinal cognitive subtypes in Parkinson's disease","volume":"46","author":"Wang","year":"2025","journal-title":"Neurol. Sci."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025006911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025006911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:23:51Z","timestamp":1761639831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025006911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":72,"alternative-id":["S1353802025006911"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107950","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive outcomes of infusion therapies in Parkinson's disease: A comprehensive systematic review","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107950"}}